1
|
Arasanz H, Bocanegra Gondan A, Teijeira L, Garnica M, Morilla Ruiz I, Chocarro L, Martínez-Aguillo M, Ausin K, Blanco E, Zuazo M, Fernandez-Hinojal G, Echaide M, Fernández-Rubio L, Pineiro-Hermida S, Ramos P, Fernández-Irigoyen J, Kochan G, Vera R, Escors D. 1074P Peripheral low-density neutrophils identify a subset of NSCLC patients with high PD-L1 tumor expression that can benefit from chemo-immunotherapy. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
2
|
Chocarro L, Blanco E, Arasanz H, Fernández-Rubio L, Bocanegra A, Echaide M, Garnica M, Ramos P, Fernández-Hinojal G, Vera R, Kochan G, Escors D. Clinical landscape of LAG-3-targeted therapy. Immunooncol Technol 2022; 14:100079. [PMID: 35755891 PMCID: PMC9216443 DOI: 10.1016/j.iotech.2022.100079] [Citation(s) in RCA: 31] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Lymphocyte-activated gene 3 (LAG-3) is a cell surface inhibitory receptor and a key regulator of immune homeostasis with multiple biological activities related to T-cell functions. LAG-3 is considered a next-generation immune checkpoint of clinical importance, right next to programmed cell death protein 1 (PD-1) and cytotoxic T-cell lymphocyte antigen-4 (CTLA-4). Indeed, it is the third inhibitory receptor to be exploited in human anticancer immunotherapies. Several LAG-3-antagonistic immunotherapies are being evaluated at various stages of preclinical and clinical development. In addition, combination therapies blocking LAG-3 together with other immune checkpoints are also being evaluated at preclinical and clinical levels. Indeed, the co-blockade of LAG-3 with PD-1 is demonstrating encouraging results. A new generation of bispecific PD-1/LAG-3-blocking agents have also shown strong capacities to specifically target PD-1+ LAG-3+ highly dysfunctional T cells and enhance their proliferation and effector activities. Here we identify and classify preclinical and clinical trials conducted involving LAG-3 as a target through an extensive bibliographic research. The current understanding of LAG-3 clinical applications is summarized, and most of the publically available data up to date regarding LAG-3-targeted therapy preclinical and clinical research and development are reviewed and discussed. LAG-3 is a highly important next-generation immune checkpoint molecule. Ninety-seven clinical trials are evaluating at least 16 LAG-3-targeting molecules. Here we identify preclinical and clinical studies conducted involving LAG-3. Bispecific LAG-3 molecules are being developed, showing strong capacities. LAG-3/PD-1 co-blockade is demonstrating encouraging results.
Collapse
Affiliation(s)
- L Chocarro
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - E Blanco
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.,Division of Gene Therapy and Regulation of Gene Expression, Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Spain
| | - H Arasanz
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.,Medical Oncology Unit, Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - L Fernández-Rubio
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - A Bocanegra
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - M Echaide
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - M Garnica
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - P Ramos
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - G Fernández-Hinojal
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.,Medical Oncology Department, Hospital Clínico San Carlos, Madrid, Spain
| | - R Vera
- Medical Oncology Unit, Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - G Kochan
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - D Escors
- Oncoimmunology Research Unit, Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| |
Collapse
|
4
|
Chocarro L, Palmeiro E, Arasanz H, Bocanegra A, Zuazo M, Echaide M, Morente P, Fernández-Rubio L, Fernández-Hinojal G, Garnica M, Ramos P, García-Granda M, Vera R, Kochan G, Escors D. 17P PD-1 and LAG-3 immune checkpoints constitutive activators exhibit differential expression phenotypes. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
5
|
Autilio C, Echaide M, Cruz A, García-Mouton C, Hidalgo A, Da Silva E, De Luca D, Sørli JB, Pérez-Gil J. Author Correction: Molecular and biophysical mechanisms behind the enhancement of lung surfactant function during controlled therapeutic hypothermia. Sci Rep 2021; 11:9990. [PMID: 33953294 PMCID: PMC8100284 DOI: 10.1038/s41598-021-89532-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Affiliation(s)
- C Autilio
- Department of Biochemistry and Molecular Biology and Research Institute "Hospital 12 de Octubre (imas12), Faculty of Biology, Complutense University, Jose Antonio Novais 12, Madrid, Spain
| | - M Echaide
- Department of Biochemistry and Molecular Biology and Research Institute "Hospital 12 de Octubre (imas12), Faculty of Biology, Complutense University, Jose Antonio Novais 12, Madrid, Spain
| | - A Cruz
- Department of Biochemistry and Molecular Biology and Research Institute "Hospital 12 de Octubre (imas12), Faculty of Biology, Complutense University, Jose Antonio Novais 12, Madrid, Spain
| | - C García-Mouton
- Department of Biochemistry and Molecular Biology and Research Institute "Hospital 12 de Octubre (imas12), Faculty of Biology, Complutense University, Jose Antonio Novais 12, Madrid, Spain
| | - A Hidalgo
- Department of Biochemistry and Molecular Biology and Research Institute "Hospital 12 de Octubre (imas12), Faculty of Biology, Complutense University, Jose Antonio Novais 12, Madrid, Spain
| | - E Da Silva
- National Research Centre for the Working Environment, Copenhagen, Denmark.,Department of Environmental Engineering, Technical University of Denmark, Kgs. Lyngby, Denmark
| | - D De Luca
- Division of Pediatrics and Neonatal Critical Care, "A.Béclère" Medical Center, Paris Saclay University Hospitals, APHP, Paris, France.,Physiopathology and Therapeutic Innovation Unit-INSERM U999, South Paris-Saclay University, Paris, France
| | - Jorid B Sørli
- National Research Centre for the Working Environment, Copenhagen, Denmark
| | - J Pérez-Gil
- Department of Biochemistry and Molecular Biology and Research Institute "Hospital 12 de Octubre (imas12), Faculty of Biology, Complutense University, Jose Antonio Novais 12, Madrid, Spain.
| |
Collapse
|
6
|
Bobatto A, Bechini F, Boggia B, Ciappina A, Echaide M, Iriart J, Urbina L, Manzo A, Rosati M, Alvo A, Corral G, Hualde M, Aquilia S, Miglioranza C. Hepatitis C: 184 patients in follow up in the direct acting antiviral era. Int J Infect Dis 2018. [DOI: 10.1016/j.ijid.2018.04.3480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
8
|
Dubcovsky J, Schlatter AR, Echaide M. Genome analysis of South American Elymus (Triticeae) and Leymus (Triticeae) species based on variation in repeated nucleotide sequences. Genome 1997; 40:505-20. [PMID: 9276937 DOI: 10.1139/g97-067] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Variation in repeated nucleotide sequences (RNSs) at the level of entire families assayed by Southern blot hybridization is remarkably low within species and is a powerful tool for scrutinizing the origin of allopolyploid taxa. Thirty-one clones from RNSs isolated from different Triticeae genera were used to investigate the genome constitution of South American Elymus. One of these clones, pHch2, preferentially hybridized with the diploid H genome Hordeum species. Hybridization of this clone with a worldwide collection of Elymus species with known genome formulas showed that pHch2 clearly discriminates Elymus species with the H genome (StH, StHH, StStH, and StHY) from those with other genome combinations (StY, StStY, StPY, and StP). Hybridization with pHch2 indicates the presence of the H genome in all South American Elymus species except Elymus erianthus and Elymus mendocinus. Hybridization with additional clones that revealed differential restriction fragments (marker bands) for the H genome confirmed the absence of the H genome in these species. Differential restriction fragments for the Ns genome of Psathyrostachys were detected in E. erianthus and E. mendocinus and three species of Leymus. Based on genome constitution, morphology, and habitat, E. erianthus and E. mendocinus were transferred to the genus Leymus.
Collapse
Affiliation(s)
- J Dubcovsky
- Department of Agronomy and Range Science, University of California, Davis 95616, USA.
| | | | | |
Collapse
|